HSHolger Strunk

Holger Strunk

*This is an algorithmically generated author record based on publicly available information.

Holger Strunk has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MR-Guided High-Intensity Focused Ultrasound (MRgFUS)

    by Holger Strunk, Susanne Hengst, Alexander Beck

  • Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers

    by Milka Marinova, Hyuliya Feradova, Maria A. Gonzalez-Carmona, Rupert Conrad, Tolga Tonguc, Marcus Thudium, Marc U. Becher, Zhou Kun, Grigor Gorchev, Slavcho Tomov, et al.

    Objectives Pancreatic cancer patients often have a high symptom burden, significantly impairing patients’ quality of life (QOL). Nevertheless, there are hardly any reports on the impact of high-intensity focused ultrasound (HIFU) on the QOL of treated patients. For the first time, this study evaluated the effect of HIFU on QOL and compared these results in two European centers. Methods Eighty patients with advanced pancreatic cancer underwent HIFU (50 in Germany, 30 in Bulgaria). Clinical assessment included evaluation of QOL and symptoms using the EORTC QLQ-C30 questionnaire at baseline and 1, 3, and 6 months after HIFU. Pain intensity was additionally evaluated with the numerical rating score (NRS). Results Compared to baseline, global health significantly improved 3 and 6 months after HIFU treatment (p = 0.02). Functional subscales including physical, emotional, and social functioning were considerably improved at 6 months (p = 0.02, p = 0.01, and p = 0.01, respectively) as were leading symptom pain (p = 0.04 at 6 months), fatigue (p = 0.03 at 3 and p = 0.01 at 6 months), and appetite loss (p = 0.01 at 6 months). Moreover, pain intensity measured by NRS revealed effective and strong pain relief at all time points (p < 0.001). Reported effects were independent of tumor stage, metastatic status, and country of treatment. Conclusions This study showed that HIFU represents an effective treatment option of advanced pancreatic cancer improving QOL by increasing global health and mitigation of physical complaints with a low rate of side effects, independent of the examiner. Therefore, HIFU is a worthwhile additional treatment besides systemic palliative chemotherapy or best supportive care in management of this aggressive disease. Key Points • In a prospective two-center study, it was shown that HIFU represents an effective treatment option of advanced pancreatic cancer improving QOL. • HIFU in pancreatic cancer patients is associated with a low rate of side effects, independent of the performer. • HIFU is a worthwhile additional treatment besides systemic palliative chemotherapy or best supportive care in management of this aggressive disease.


  • Fortgeschrittenes Pankreaskarzinom: Hoch-intensiver fokussierter Ultraschall (HIFU) und andere lokal ablative Verfahren

    by Milka Marinova, Timo Wilhelm-Buchstab, Holger Strunk

    Zusammenfassung: Hintergrund Das lokal fortgeschrittene Pankreaskarzinom ist ein lebenslimitierender Tumor mit einer Vielzahl von Symptomen, u. a. Tumorschmerz. Lokal ablative Verfahren, die thermische oder auch nichtthermische Techniken anwenden, können als moderne Therapieoptionen zur Tumorkontrolle und symptomatischen Verbesserung eingesetzt werden. Dieser Artikel gibt einen Überblick über die derzeit verfügbaren Behandlungsverfahren und -ergebnisse, einschließlich unserer eigenen Erfahrungen mit dem hoch-intensiven fokussierten Ultraschall (HIFU). Methode Unsere Erfahrungen mit der HIFU-Therapie beim Pankreaskarzinom basieren auf 89 Patienten (UICC III-IV). Neben den HIFU-Ergebnissen wurden Ergebnisse zur lokalen Tumorkontrolle, Sicherheit sowie Mortalität und behandlungsabhängigen Veränderung von Symptomen aus publizierten Studien zur Radiofrequenz-, Mikrowellen- und Kryoablation, irreversiblen Elektroporation und stereotaktischen Strahlentherapie einbezogen. Ergebnisse Obwohl die unterschiedlichen Modalitäten überwiegend sicher durchführbar sind, bietet der HIFU mit seiner Nicht-Invasivität einen entscheidenden methodischen Vorteil. Mit HIFU konnte bei 85% der Patienten eine effektive und lang anhaltende Schmerzlinderung erreicht werden; bei 50% war nach 6 Wochen keinerlei analgetische Medikation erforderlich. Leider sind Schmerzlinderung und Lebensqualität bei den anderen lokalen Behandlungsmethoden nur selten untersucht. Eine Tumormassenreduktion konnte mit allen ablativen Therapien erreicht werden, wobei diese 6 Monate nach HIFU im Mittel bei 60% lag. Unterschiede in der behandlungsassoziierten Morbidität wurden berichtet, sind jedoch aufgrund der unausgewogenen Studienpopulationen nur eingeschränkt vergleichbar. Schlussfolgerung Eine Vielzahl an lokal ablativen Behandlungsmodalitäten sind zur Tumormassenreduktion beim fortgeschrittenen Pankreaskarzinom verfügbar, bieten aber unterschiedlichen symptomatischen Nutzen. Eine effektive und lang anhaltende Reduktion von Tumorschmerzen ohne Einführen von Nadeln oder Elektroden in den Tumorbereich bietet ausschließlich das HIFU-Verfahren. Randomisierte, kontrollierte klinische Studien zum direkten Vergleich der hier vorgestellten Modalitäten sind in der näheren Zukunft zu befürworten.

  • Assessment of Echogenicity of Thyroid Nodules

    by Holger M. Strunk, Milka Marinova

    Dear Editor, We read with interest the article by Dr. Bojunga in Ultraschall in der Medizin entitled “Ultrasound for Thyroid Nodules” [1]. This is a well-written and clearly structured education article. However, there is one statement that needs clarification. On pages 490 and 491, the author explains that “echogenicity is subdivided into hyperechoic, isoechoic, hypoechoic as well as distinctly hypoechoic, in each case related to the striated neck muscles”. In our opinion, this is not correct and only applies for the distinction of (moderate) hypoechoic (for example TIRADS 4) to distinctly hypoechoic (for example TIRADS 5) lesions [2]. In the captions, for example for figure 2, the author even clearly compares the echogenicity of the isoechoic nodule to the surrounding thyroid parenchyma and not to the neck muscles.

  • Open Access

    Transjugular Intrahepatic Portosystemic Shunt (TIPS): Pathophysiologic Basics, Actual Indications and Results with Review of the Literature

    by Holger Strunk, Milka Marinova

    Background Transjugular intrahepatic portosystemic shunt (TIPS) is a non-selective portosystemic shunt created using endovascular techniques. During recent years technical improvements and new insights into pathophysiology have modified indications for TIPS placement. In this article we therefore want to discuss current knowledge. Method A literature review was performed to review and discuss the pathophysiology, indications and results of the TIPS procedure. Results Established TIPS indications are persistent bleeding despite combined pharmacological and endoscopic therapy and rebleeding during the first five days. A new indication in the European recommendations is early TIPS placement within 72 hours, ideally within 24 hours, in patients bleeding from esophageal or gastroesophageal varices at high risk for treatment failure (e. g. Child-Pugh class C < 14 points or Child-Pugh class B with active bleeding) after initial pharmacological and endoscopic therapy. For prevention of recurrent variceal hemorrhage in the recommendations, covered TIPS placement is the treatment of choice only after failed first-line therapy, although numerous TIPS studies show a prolonged time to rebleeding and a reduction of mortality. Similarly for secondary prophylaxis in patients with refractory ascites, covered TIPS placement may be considered only if the patient continues to be intolerant to NSBBs and is an appropriate TIPS candidate even though studies show that the TIPS procedure controls ascites, improves survival and renal function better than paracentesis. Potential indications for TIPS implantation are Budd-Chiari syndrome, acute portal vein thromboses, hydrothorax, hepatopulmonary and hepatorenal syndrome (Typ 2), portal hypertensive gastropathy (PHG) and prophylaxis of complications of abdominal surgery, very rarely bleeding in ectopic varices or in patients with chylothorax or chylous ascites. Conclusion TIPS placement is an established procedure with a new indication as “early TIPS”. In the European recommendations it is only the second-line therapy for prevention of recurrent variceal hemorrhage and for secondary prophylaxis in patients with refractory ascites although several studies showed a clear benefit of the TIPS procedure compared to ligation and NSBBs. Key Points Citation Format


  • Champagner im Blut oder Mikrobläschen in Medizin und Gastronomie (eine nicht ganz so ernst gemeinte wissenschaftliche Betrachtung)

    by Holger Strunk, Gerd Stuckmann, Milka Marinova

    Wie lieb und luftig perlt die Blase Der Witwe Klicko in dem Glase (Wilhelm Busch, Die fromme Helene, Kapitel 9) Une coupe de Champagne lave la poussière de toute la journée (Pierre LeMoullac, Sommelier des Restaurant „L’Ambroisie“ Paris) Basis der kontrastverstärkten Sonografie, contrast-enhanced Ultrasonography (CEUS) sind gasgefüllte Kügelchen mit einer extrem dünnen Hülle aus Eiweißen und Lipiden (für Liebhaber chemischer Bezeichnungen: Hexafluorosulfid umgeben von einer Kapsel aus Distearoylphosphatidyl-cholin und Natrium-Dipalmoitylphosphatidylglycerol sowie Palmitinsäure), wodurch sich dem kulinarisch Interessierten direkt ein Vergleich mit denen im Champagner aufdrängt.

  • Mesenteric Vessel Patency Following HIFU Therapy in Patients with Locally Invasive Pancreatic Cancer

    by Holger M. Strunk, Caroline Lützow, Jana Henseler, Martin Mücke, Maximilian Rauch, Christian Marx, Hans H. Schild, Milka Marinova

    Purpose To evaluate the effects of HIFU therapy on visceral vessel patency in patients with inoperable locally invasive pancreatic cancer. Materials and Methods 50 pancreatic cancer patients (26 men, 24 women) aged 41 – 82 years (65.0 ± 10.2) underwent ultrasonography (US) and computed tomography (CT) examinations before and within one day after HIFU treatment, as well as at follow-up at six weeks, three months and six months. Evaluation and grading were performed by two experienced independent radiologists according to a classification scheme based on vessel involvement, vessel diameter, patency, and defects in flow. Results Before HIFU treatment, arterial vessel involvement was noted in 42 patients, venous involvement in 47, and 47 patients presented with both. Superior mesenteric artery occlusion was found in three carcinomas while nearly half of the cases (n = 24) displayed signs of superior mesenteric vein, portal vein, or splenic vein occlusion. High-grade tumor-associated arterial narrowing was seen in ten patients. Despite vessel encasement and partially extensive propagation of collateral vessels, it was possible to safely perform HIFU treatment in all patients without complications. US and CT studies performed within one day after therapy did not show any change in vessel patency in 47 patients (94 %). Follow-up controls at the six-week mark revealed increased vessel narrowing and finally occlusion after six months in 11 patients due to tumor progression. Conclusion This study demonstrates that HIFU treatment can be safely applied to pancreatic cancers enveloping large mesenteric vessels despite vessel narrowing or extensive collateral propagation. Most patients (94 %) did not experience adverse effects regarding vessel patency.


  • High intensity focused ultrasound for the treatment of advanced liver cancer

    by Maximilian Rauch, Milka Marinova, Hans Heinz Schild, Holger Strunk


  • Open Access

    Thermometry during coblation and radiofrequency ablation of vertebral metastases: a cadaver study

    by Simon F. Groetz, Klaus Birnbaum, Carsten Meyer, Holger Strunk, Hans H. Schild, Kai E. Wilhelm

    To evaluate safety of coblation of simulated lytic metastases in human cadaveric vertebral bodies by measuring heat distribution during thermal tissue ablation and comparing it to radiofrequency ablation (RFA). Three devices were compared: a 10 mm single-needle RFA electrode, a 20 mm array RFA electrode and the coblation device. To simulate bone metastases, a spinal tumor model was used stuffing a created lytic cavity with muscle tissue. Measuring of heat distribution was performed during thermal therapy within the vertebral body, in the epidural space and at the ipsilateral neural foramen. Eight vertebral bodies were used for each device. Temperatures at heat-sensitive neural structures during coblation were significantly lower than using RFA. Maximum temperatures measured at the end of the procedure at the neural foramen: 46.4 °C (±2.51; RFA 10 mm), 52.2 °C (±5.62; RFA 20 mm) and 42.5 °C (±2.88; coblation). Maximum temperatures in the epidural space: 46.8 °C (±4.7; RFA 10 mm), 49.5 °C (±6.48; RFA 20 mm) and 42.1 °C (±2.5; coblation). Maximum temperatures measured within the vertebral body: 50.6 °C (±10.48; RFA 10 mm), 61.9 °C (±15.39; RFA 20 mm) and 54.4 °C (±15.77; coblation). In addition to RFA, the application of coblation is a safe method to ablate vertebral lesions with regards to heat distribution at heat-sensitive neural spots. The measured temperatures did not harbor danger of thermal damage to the spinal cord or the spinal nerves.